Long Position on REGN @ $186.00 on 12/6/2012 (Momentum)

Regeneron Pharmaceuticals (REGN) discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States.

The company’s commercial products include EYLEA (aflibercept) Injection for the treatment of neovascular age-related macular degeneration; and ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children.

Its products under Phase III clinical development stage consists of EYLEA for the treatment of serious eye diseases; ZALTRAP (Aflibercept), which is developed in oncology; and ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment. The company’s earlier stage clinical programs include various human monoclonal antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction; REGN88 for rheumatoid arthritis; REGN668 for atopic dermatitis and eosinophilic asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN728, REGN1033, and REGN1154.

It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. 

Shares have formed a bullish "flag" and are expected to move higher out of this formation.

52-Week Trading Range:  $50.27 - $188.95

Last Trade:  $186.00

Stop Loss:  $176.70

Target Price:  $204.60

Position closed on 12/19/2012 at price of $176.70 with a -5.00% loss in 13 days.

Back to Portfolio